logo
Twitter
Discord
Email
logo
Atlantic International Corp.

Atlantic International Corp.

NASDAQ•ATLN
CEO: Mr. Jeffrey M. Jagid
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2021-08-27
Atlantic International Corp., through its subsidiaries, operates as a staffing company servicing the commercial, professional, finance, direct placement, and managed service provider verticals. The company specializes in permanent, temporary, and temporary-to-permanent placement services in various areas, including accounting and finance, administrative and clerical, hospitality, information technology, legal, light industrial, and medical fields. It also provides productivity consulting and workforce management solutions. Atlantic International Corp. was founded in 2018 and is based in Englewood Cliffs, New Jersey.
Contact Information
270 Sylvan Avenue, Suite 2230, Englewood Cliffs, NJ, 07632, United States
201-899-4470
www.atlantic-international.com
Market Cap
$225.91M
P/E (TTM)
-2.1
25.7
Dividend Yield
--
52W High
$6.50
52W Low
$1.16
52W Range
51%
Rank65Top 96.0%
1.6
F-Score
Modified Piotroski Analysis
Based on 9-year fundamentals
Weak • 1.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2025

Financial Dashboard

Q3 2025 Data

Revenue

$110.13M+2.15%
4-Quarter Trend

EPS

-$0.20+25.00%
4-Quarter Trend

FCF

-$1.27M-6.41%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Service revenue net reached $315.833M for nine months, marking a 0.9% increase versus 2024.
Net Loss Significantly Reduced Nine-month net loss $32.283M, significantly reduced by 51.7% compared to the prior year period.
Gross Profit Margin Expansion Gross profit $35.007M, increasing 3.4% driven by successful initiative selling higher margin accounts.
Total Debt Reduction Total debt decreased to $76.386M as of September 30, 2025, down from $80.589M year-end.

Risk Factors

Key Debt Instruments Default Term Note and Seller Notes obligations are currently in default status, requiring immediate restructuring efforts.
Future Liquidity Requirements Cash flow insufficient to cover Merger Note maturity of $35.000M due March 31, 2027, requiring new financing.
Stockholder Dilution Potential Future debt or equity financing may cause substantial stockholder dilution if additional capital is required.
Legacy Settlement Contingency Significant accrued liabilities remain for legacy stockholder settlements, with some payments still pending finalization.

Outlook

New ABL Facility Capacity New ABL facility provides $342.712K borrowing capacity, expected to fund operations for at least one year.
Debt Restructuring Priority Management actively negotiating to refinance or satisfy Assumed Debt obligations to remove joint liability.
Internal Control Remediation Plan Plans to implement improved internal controls by end of 2025/early 2026 to remediate material weaknesses identified.
New Equity Incentive Plan Approved 2025 Omnibus Equity Incentive Plan reserving 10.0M shares for future grants to employees and non-employees.

Peer Comparison

Revenue (TTM)

Atlantic International Corp.ATLN
$445.38M
+3.8%
Health Catalyst, Inc.HCAT
$316.06M
+4.6%
MDxHealth SAMDXH
$152.99M
+80.6%

Gross Margin (Latest Quarter)

Orchestra BioMed Holdings, Inc.OBIO
94.3%
+1.2pp
Invivyd, Inc.IVVD
91.7%
+0.4pp
Aclaris Therapeutics, Inc.ACRS
83.7%
+39.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ACRS$487.55M-3.9-102.8%1.3%
IVVD$280.06M-6.0-93.0%1.9%
PRE$243.91M-5.5-28.9%1.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-5.3%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 27, 2026
|
EPS:-
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 14, 2025|
    Revenue: $110.13M+2.2%
    |
    EPS: $-0.20+25.0%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 14, 2025|
    Revenue: $102.90M-1.7%
    |
    EPS: $-0.20-89.8%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $102.81M+2.2%
    |
    EPS: $-0.20+364.0%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 28, 2025|
    Revenue: $442.61M+10.3%
    |
    EPS: $-3.68-513.3%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 14, 2024|
    Revenue: $107.80M+10.2%
    |
    EPS: $-0.16+220.6%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 14, 2024|
    Revenue: $104.64M+17.1%
    |
    EPS: $-1.96+3450.7%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 17, 2024|
    Revenue: $100.62M+2.6%
    |
    EPS: $-0.04-41.0%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 10, 2024|
    Revenue: $401.37M-9.1%
    |
    EPS: $-0.60-215.8%
    N/A